Boehringer Ingelheim secures novel immune checkpoint inhibitor with acquisition of Nerio Therapeutics Read more
Novartis Scemblix granted FDA Priority Review for the treatment of adults with newly diagnosed CML Read more
Sandoz launches biosimilar Pyzchiva (ustekinumab) across Europe, to treat chronic inflammatory diseases Read more
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease Read more
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor Read more
Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy Read more
Bayer announces positive topline results for NUBEQA (darolutamide) from Phase III trial in men with metastatic hormone-sensitive prostate cancer (mHSPC) Read more
Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms Read more
CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab Read more
Merck Begins Commercial Production of First GMP-Compliant Manufacturing Line for Cell Culture Media in China Read more